09/807013
JC02 Rec'd PCT/PTO 06 APR 2001

Patent
Attorney's Docket No. 004080-164

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	
	)	
Gunnar NORSTEDT et al	)	Group Art Unit: Unassigned
	)	
Application No.: TBA (§371 of PCT/SE99/01788)	)	Examiner: Unassigned
	)	
Filed: Herewith	)	
	)	
For: USE OF SOCS-2 OR CIS TO SCREEN FOR COMPOUNDS ENHANCING GROWTH HORMONE EFFECT	)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Copies of the references have been forwarded to the U.S. Designated/Elected Office by WIPO.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____
Malcolm K. McGowan, Ph.D.
Registration No. 39,300

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620
Date: 6 April 2001

(11/00)

09/807013
Rec'd PCT/PTO 06 APR 2001

Patent
Attorney's Docket No. 004080-164

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	
Gunnar NORSTEDT et al	Group Art Unit: Unassigned
Application No.: TBA (§371 of PCT/SE99/01788)	Examiner: Unassigned
Filed: Herewith	
For: USE OF SOCS-2 OR CIS TO SCREEN FOR COMPOUNDS ENHANCING GROWTH HORMONE EFFECT	

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

[X] No additional fee for submission of an IDS is required.

[] The fee of $180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.

[] A certification under 37 C.F.R. § 1.97(e) is also enclosed.

[] A certification under 37 C.F.R. § 1.97(e), and the fee of $180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.

[] Charge $_____ to Deposit Account No. 02-4800 for the fee due.

[] A check in the amount of $_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____
Malcolm K. McGowan, Ph.D.
Registration No. 39,300

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: April 6, 2001

INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO.	APPLICATION NO.
004080-164	TBA (§371 of PCT/SE99/01788)
APPLICANT: Gunnar NORSTEDT et al	
FILING DATE: Herewith	GROUP: Unassigned

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes	Translation No
	WO9820023	05/1998	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Adams et al, "Growth Hormone Preferentially Induces the Rapid, Transient Expression of SOCS-3, a Novel Inhibitor of Cytokine Receptor Signaling", *JBC - Adams et al*, Vol. 273, No. 3, p. 1285-1287 (1999)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.